RecruitingNot applicableNCT06688422
Official study title

Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy

Study summary

The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are: Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life? Participants will: Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake. Continue using the spirometer daily during treatment and for up to three months after treatment. Complete quality of life assessments at the start of the study and at 3, 6, and 12 months. Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedincentive spirometry

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?The Cooper Health System

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
The Cooper Health System
Interventions being studied
Device: incentive spirometry
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Confirmed diagnosis of advanced non-small-cell lung cancer
  • Performance status (ECOG 0-1)
  • Eligible for concurrent chemotherapy and radiation
  • 18 years or older
Reasons someone may not be able to joinExclusion criteria
  • Previous lung or thoracic surgery
  • Enrollment in another pulmonary intervention trial
  • Home oxygen usage prior to enrolment
  • Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging
  • Presence of active respiratory tract infection
  • Uncontrolled nausea and vomiting
  • Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy
  • Inability or unwillingness of individual to give written informed consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • MD Anderson Cancer Center at CooperCamden, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 15, 2026. Always confirm current availability with the study team.

View original record ↗